Skip to main content
. 2015 Nov 26;7(3):2921–2935. doi: 10.18632/oncotarget.6404

Figure 5. The erbB3 receptor and IGF-1R initiates activation of distinct downstream signaling pathways in trastzumab-resistant breast cancer cells.

Figure 5

SKBR3-Pool2 and BT474-HR20 cells infected with lentivirus containing either ConshRNA or erbB3/IGF-1R shRNA (erbB3shRNA or IGF-1RshRNA). The cells were then untreated or treated with lapatinib (0.1 μmol/L) for 24 hr. Cells were collected and subjected to western blot analyses of erbB3, IGF-1R, P-Src (Y416), Src, P-Akt (S473), Akt, P-MAPK (Erk1/2) (T202/Y204), MAPK (Erk1/2), or β-actin.